These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma. García-Sanz R; González-López TJ; Vázquez L; Hermida G; Graciani IF; San Miguel JF Eur J Haematol; 2010 Mar; 84(3):266-70. PubMed ID: 19912314 [TBL] [Abstract][Full Text] [Related]
4. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. Al-Ali HK; Wittekind C; Niederwieser D Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864 [TBL] [Abstract][Full Text] [Related]
5. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy. Kirchner EM; Ebsen M; Kirchner J; Theegarten D; Voigtmann R Ann Oncol; 2001 Aug; 12(8):1169-71. PubMed ID: 11583202 [TBL] [Abstract][Full Text] [Related]
6. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Shankar A; Hayward J; Kirkwood A; McCarthy K; Hewitt M; Morland B; Daw S Br J Haematol; 2014 May; 165(4):534-44. PubMed ID: 24754633 [TBL] [Abstract][Full Text] [Related]
7. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751 [TBL] [Abstract][Full Text] [Related]
8. Ifosfamide, epirubicin and etoposide (IEV) therapy in relapsed and refractory high-grade non-Hodgkin's lymphoma and Hodgkin's disease. Zinzani PL; Barbieri E; Visani G; Gherlinzoni F; Perini F; Neri S; Bendandi M; Ammendolia I; Salvucci M; Babini L Haematologica; 1994; 79(6):508-12. PubMed ID: 7534744 [TBL] [Abstract][Full Text] [Related]
9. Rituximab in combination with interferon-alpha in relapsed and refractory diffuse large B-cell non-Hodgkin's lymphoma. Bertè R; Vallisa D; Civardi G; Moroni CF; Lazzaro A; Cavanna L Acta Haematol; 2001; 106(3):141-2. PubMed ID: 11713384 [No Abstract] [Full Text] [Related]
10. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl. Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142 [TBL] [Abstract][Full Text] [Related]
11. Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation. Mian M; Farsad M; Pescosta N; Casini M; Cavattoni IM; Deola S; Cortelazzo S Ann Hematol; 2013 Jan; 92(1):121-3. PubMed ID: 22820997 [No Abstract] [Full Text] [Related]
12. Standard therapy of advanced Hodgkin lymphoma. Kuruvilla J Hematology Am Soc Hematol Educ Program; 2009; ():497-506. PubMed ID: 20008235 [TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for Hodgkin's disease. Ekert H N Engl J Med; 2003 Sep; 349(12):1186-7; author reply 1186-7. PubMed ID: 13679536 [No Abstract] [Full Text] [Related]
14. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer]. Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945 [TBL] [Abstract][Full Text] [Related]
15. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Weihrauch MR; Re D; Scheidhauer K; Ansén S; Dietlein M; Bischoff S; Bohlen H; Wolf J; Schicha H; Diehl V; Tesch H Blood; 2001 Nov; 98(10):2930-4. PubMed ID: 11698273 [TBL] [Abstract][Full Text] [Related]
16. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. Sieber M; Tesch H; Pfistner B; Rueffer U; Lathan B; Brosteanu O; Paulus U; Koch T; Pfreundschuh M; Loeffler M; Engert A; Josting A; Wolf J; Hasenclever D; Franklin J; Duehmke E; Georgii A; Schalk KP; Kirchner H; Doelken G; Munker R; Koch P; Herrmann R; Greil R; Anselmo AP; Diehl V J Clin Oncol; 2002 Jan; 20(2):476-84. PubMed ID: 11786577 [TBL] [Abstract][Full Text] [Related]